Prostate cancer survivorship: Prevention and treatment of the adverse effects of androgen deprivation therapy

Journal of General Internal Medicine

Volumn 24, Issue SUPPL. 2, 2009, Pages

  Saylor, Philip J ^a   Keating, Nancy L ^b   Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bisphosphonates; Cardiovascular disease; Cardiovascular disease.agonists; Diabetes; GnRH agonists; Obesity; Osteoporosis; Prostate cancer; Survivorship

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; DENOSUMAB; GONADORELIN AGONIST; PAMIDRONIC ACID; PLACEBO; TOREMIFENE; TRIACYLGLYCEROL; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; BONE DENSITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; FATIGUE; FLUSHING; FRACTURE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIBIDO DISORDER; METABOLIC DISORDER; MORBIDITY; MUSCLE ATROPHY; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; PRIMARY MEDICAL CARE; PROSTATE CANCER; REVIEW;

ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FRACTURES, BONE; HUMANS; MALE; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 71949109680     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-009-0968-y     Document Type: Review

References (88)

1. Surveillance, Epidemiology and End Results (SEER): Stat Fact Sheets: Prostate Cancer. 2008. (Accessed at http://seer.cancer.gov/statfacts/html/prost. html).
2. ED Crawford MA Eisenberger DG McLeod, et al. 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321 7 419 424 1:STN:280:DyaL1MzksVWgtw%3D%3D 2503724
3. MA Eisenberger BA Blumenstein ED Crawford, et al. 1998 Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 339 15 1036 1042 10.1056/NEJM199810083391504 1:CAS:528:DyaK1cXmvV2itr8%3D 9761805 (Pubitemid 28457865)
4. CM Tangen JR Faulkner ED Crawford, et al. 2003 Ten-year survival in patients with metastatic prostate cancer Clin Prostate Cancer 2 1 41 45 15046683
5. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med. 1984;311(20):1281-6.
6. NJ Vogelzang GW Chodak MS Soloway, et al. 1995 Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group Urology 46 2 220 226 10.1016/S0090-4295(99)80197-6 1:STN:280:DyaK2MzltV2jtw%3D%3D 7624991
7. MJ Barry MA Delorenzo ES Walker-Corkery FL Lucas DC Wennberg 2006 The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study BJU Int 98 5 973 978 10.1111/j.1464-410X.2006.06416.x 16879443 (Pubitemid 44536442)
8. VB Shahinian YF Kuo JL Freeman E Orihuela JS Goodwin 2005 Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer 103 8 1615 1624 10.1002/cncr.20955 1:CAS:528:DC%2BD2MXjvVymtb8%3D 15742331 (Pubitemid 40490022)
9. NL Keating AJ O'Malley MR Smith 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 27 4448 4456 10.1200/JCO.2006.06.2497 1:CAS:528:DC%2BD28XhtVyisrrK 16983113 (Pubitemid 46630983)
10. PC Walsh 1997 Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group J Urol 158 4 1623 1624 10.1016/S0022-5347(01)64270-8 1:STN:280:DyaK2svksFyquw%3D%3D 9302187 (Pubitemid 127739855)
11. M Bolla L Collette L Blank, et al. 2002 Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 9327 103 106 10.1016/S0140-6736(02)09408-4 1:CAS:528:DC%2BD38Xlt1Ohuro%3D 12126818 (Pubitemid 34786197)
12. AV D'Amico J Manola M Loffredo AA Renshaw A DellaCroce PW Kantoff 2004 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial Jama 292 7 821 827 10.1001/jama.292.7.821 15315996 (Pubitemid 39079668)
13. EM Messing J Manola J Yao, et al. 2006 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 6 472 479 10.1016/S1470-2045(06)70700-8 1:CAS:528:DC%2BD28XltFClsLo%3D 16750497 (Pubitemid 43779173)
14. DA Loblaw KS Virgo R Nam, et al. 2007 Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 12 1596 1605 10.1200/JCO.2006.10.1949 1:CAS:528:DC%2BD2sXlsVynurs%3D 17404365 (Pubitemid 46733088)
15. GL Lu-Yao PC Albertsen DF Moore, et al. 2008 Survival following primary androgen deprivation therapy among men with localized prostate cancer Jama 300 2 173 181 10.1001/jama.300.2.173 1:CAS:528:DC%2BD1cXosVWqt70%3D 18612114 (Pubitemid 351969301)
16. VB Shahinian YF Kuo JL Freeman JS Goodwin 2005 Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2 154 164 10.1056/NEJMoa041943 1:CAS:528:DC%2BD2MXksFajuw%3D%3D 15647578 (Pubitemid 40096612)
17. CJ Ryan EP Elkin J Cowan PR Carroll 2007 Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE Cancer 110 1 81 86 10.1002/cncr.22736 17516446 (Pubitemid 46986421)
18. P Hakimian M Blute Jr. J Kashanian S Chan D Silver R Shabsigh 2008 Metabolic and cardiovascular effects of androgen deprivation therapy BJU Int 102 11 1509 1514 10.1111/j.1464-410X.2008.07933.x 18727614
19. F Saad JD Adachi JP Brown, et al. 2008 Cancer treatment-induced bone loss in breast and prostate cancer J Clin Oncol 26 33 5465 5476 10.1200/JCO.2008.18. 4184 18955443
20. PR Ebeling 2008 Clinical practice. Osteoporosis in men N Engl J Med 358 14 1474 1482 10.1056/NEJMcp0707217 1:CAS:528:DC%2BD1cXktlSgt7o%3D 18385499
21. E Seeman 1999 The structural basis of bone fragility in men Bone 25 1 143 147 10.1016/S8756-3282(99)00117-9 1:STN:280:DyaK1MzkvF2jtg%3D%3D 10423041 (Pubitemid 29322080)
22. JP Bilezikian 1999 Osteoporosis in men J Clin Endocrinol Metab 84 10 3431 3434 10.1210/jc.84.10.3431 1:CAS:528:DyaK1MXms1Ohsbg%3D 10522975
23. JF Maillefert J Sibilia F Michel C Saussine RM Javier C Tavernier 1999 Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma J Urol 161 4 1219 1222 10.1016/S0022-5347(01)61639-2 1:CAS:528:DyaK1MXitVers70%3D 10081873 (Pubitemid 29426121)
24. MR Smith FJ McGovern AL Zietman, et al. 2001 Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 13 948 955 10.1056/NEJMoa010845 1:CAS:528:DC%2BD3MXntlehtbs%3D 11575286 (Pubitemid 34940810)
25. A Berruti L Dogliotti C Terrone, et al. 2002 Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy J Urol 167 6 2361 1367 10.1016/S0022- 5347(05)64985-3 11992038 discussion 7
26. HW Daniell SR Dunn DW Ferguson G Lomas Z Niazi PT Stratte 2000 Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 163 1 181 186 10.1016/S0022-5347(05)68000-7 1:STN:280: DC%2BD3c%2Fmslygsw%3D%3D 10604342
27. T Diamond J Campbell C Bryant W Lynch 1998 The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy Cancer 83 8 1561 1566 10.1002/(SICI)1097-0142(19981015)83: 8<1561::AID-CNCR11>3.0.CO;2-Z 1:CAS:528:DyaK1cXntVeju7w%3D 9781950 (Pubitemid 28465474)
28. MR Smith J Eastham DM Gleason D Shasha S Tchekmedyian N Zinner 2003 Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 6 2008 2012 10.1097/01.ju.0000063820.94994.95 1:CAS:528:DC%2BD3sXktlOis7w%3D 12771706 (Pubitemid 36576705)
29. MR Smith WC Lee J Brandman Q Wang M Botteman CL Pashos 2005 Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 31 7897 7903 10.1200/JCO.2004.00.6908 1:CAS:528:DC%2BD2MXht1Cqs7fI 16258089 (Pubitemid 46657388)
30. MR Smith SP Boyce E Moyneur MS Duh MK Raut J Brandman 2006 Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer J Urol 175 1 136 139 10.1016/S0022-5347(05)00033-9 1:CAS:528:DC%2BD28XntlWktw%3D%3D 16406890 discussion 9 (Pubitemid 41797111)
31. MR Smith FJ McGovern AL Zietman, et al. 2001 Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer N Engl J Med 345 13 948 955 10.1056/NEJMoa010845 1:CAS:528:DC%2BD3MXntlehtbs%3D 11575286 (Pubitemid 34940810)
32. TH Diamond J Winters A Smith, et al. 2001 The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study Cancer 92 6 1444 1450 10.1002/1097-0142(20010915)92:6<1444::AID- CNCR1468>3.0.CO;2-M 1:CAS:528:DC%2BD3MXnvVygsr4%3D 11745221 (Pubitemid 32947828)
33. MR Smith J Eastham D Gleason D Shasha S Tchekmedyian N Zinner 2003 Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 6 2008 2012 10.1097/01.ju.0000063820.94994.95 1:CAS:528: DC%2BD3sXktlOis7w%3D 12771706 (Pubitemid 36576705)
34. MD Michaelson DS Kaufman H Lee, et al. 2007 Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer J Clin Oncol 25 9 1038 1042 10.1200/JCO.2006.07.3361 1:CAS:528:DC%2BD2sXksVyrs74%3D 17369566 (Pubitemid 46596753)
35. SL Greenspan JB Nelson DL Trump NM Resnick 2007 Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Ann Intern Med 146 6 416 424 17371886
36. MR Smith MA Fallon H Lee JS Finkelstein 2004 Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial J Clin Endocrinol Metab 89 8 3841 3846 10.1210/jc.2003-032058 1:CAS:528:DC%2BD2cXmslKmtLc%3D 15292315 (Pubitemid 39071482)
37. MR Smith SB Malkowicz F Chu, et al. 2008 Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study J Urol 179 1 152 155 10.1016/j.juro.2007.08.137 1:STN:280:DC%2BD2sjjvVWrsw%3D%3D 18001802 (Pubitemid 350216737)
38. Smith M, Morton R, Wallace H, et al. A Phase III randomized controlled trial of toremifene to prevent fractures and other adverse effects of androgen therapy in men with prostate cancer. In: American Association for Cancer Research Annual Meeting 2008; 2008 April 12-16, 2008; San Diego, CA: AACR Meeting Abstracts Online; 2008.
39. PJ Bekker DL Holloway AS Rasmussen, et al. 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 7 1059 1066 10.1359/JBMR.040305 1:CAS:528:DC%2BD2cXlvFWrtr0%3D 15176987 (Pubitemid 41110556)
40. JJ Body T Facon RE Coleman, et al. 2006 A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Clin Cancer Res 12 4 1221 1228 10.1158/1078-0432.CCR-05-1933 1:CAS:528:DC%2BD28XhsFaltLg%3D 16489077 (Pubitemid 43342512)
41. GK Ellis HG Bone R Chlebowski, et al. 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 30 4875 4882 10.1200/JCO.2008.16.3832 1:CAS:528:DC%2BD1cXhtlGitrzO 18725648
42. EM Lewiecki PD Miller MR McClung, et al. 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD J Bone Miner Res 22 12 1832 1841 10.1359/jbmr.070809 1:CAS:528:DC%2BD2sXhsVyjtrjF 17708711 (Pubitemid 351229299)
43. MR McClung EM Lewiecki SB Cohen, et al. 2006 Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 8 821 831 10.1056/NEJMoa044459 1:CAS:528:DC%2BD28Xhsl2gs7o%3D 16495394 (Pubitemid 43290920)
44. C De Laet A Oden H Johansson O Johnell B Jonsson JA Kanis 2005 The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach Osteoporos Int 16 3 313 318 10.1007/s00198-004-1689-z 15241584 (Pubitemid 40379431)
45. JA Kanis O Johnell A Oden C De Laet B Jonsson A Dawson 2002 Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies Bone 30 1 251 258 10.1016/S8756-3282(01)00653-6 1:STN:280: DC%2BD38%2FmvVWmug%3D%3D 11792594 (Pubitemid 34044325)
46. JA Kanis O Johnell A Oden H Johansson E McCloskey 2008 FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 4 385 397 10.1007/s00198-007-0543-5 1:STN:280:DC%2BD1c7nvF2ntA%3D%3D 18292978
47. C De Laet JA Kanis A Oden, et al. 2005 Body mass index as a predictor of fracture risk: a meta-analysis Osteoporos Int 16 11 1330 1338 10.1007/s00198-005-1863-y 15928804 (Pubitemid 41532085)
48. O Johnell JA Kanis A Oden, et al. 2005 Predictive value of BMD for hip and other fractures J Bone Miner Res 20 7 1185 1194 10.1359/JBMR.050304 15940371 (Pubitemid 40863806)
49. JA Kanis H Johansson O Johnell, et al. 2005 Alcohol intake as a risk factor for fracture Osteoporos Int 16 7 737 742 10.1007/s00198-004-1734-y 15455194 (Pubitemid 40933589)
50. JA Kanis H Johansson A Oden, et al. 2005 A meta-analysis of milk intake and fracture risk: low utility for case finding Osteoporos Int 16 7 799 804 10.1007/s00198-004-1755-6 15502959 (Pubitemid 40933596)
51. JA Kanis H Johansson A Oden, et al. 2004 A family history of fracture and fracture risk: a meta-analysis Bone 35 5 1029 1037 10.1016/j.bone.2004.06.017 1:STN:280:DC%2BD2crmvV2kug%3D%3D 15542027 (Pubitemid 39487348)
52. JA Kanis H Johansson A Oden, et al. 2004 A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 19 6 893 899 10.1359/JBMR.040134 15125788 (Pubitemid 41103445)
53. JA Kanis O Johnell C De Laet, et al. 2004 A meta-analysis of previous fracture and subsequent fracture risk Bone 35 2 375 382 10.1016/j.bone.2004.03. 024 1:STN:280:DC%2BD2czmsVCntg%3D%3D 15268886 (Pubitemid 38953182)
54. JA Kanis O Johnell A Oden, et al. 2005 Smoking and fracture risk: a meta-analysis Osteoporos Int 16 2 155 162 10.1007/s00198-004-1640-3 1:STN:280:DC%2BD2M%2FksVentA%3D%3D 15175845 (Pubitemid 40193202)
55. Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): What They Mean to the Bone Densitometrist and Bone Technologist. J Clin Densitom 2008.
56. DH Bessesen 2008 Update on obesity J Clin Endocrinol Metab 93 6 2027 2034 10.1210/jc.2008-0520 1:CAS:528:DC%2BD1cXntFamsLY%3D 18539769 (Pubitemid 351831511)
57. A Vermeulen S Goemaere JM Kaufman 1999 Testosterone, body composition and aging J Endocrinol Invest 22 5 Suppl 110 116 1:STN:280:DyaK1MzmvFWrtg%3D%3D 10442580
58. MR Smith JS Finkelstein FJ McGovern, et al. 2002 Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2 599 603 10.1210/jc.87.2.599 1:CAS:528:DC%2BD38XhsVSju74%3D 11836291 (Pubitemid 34158224)
59. MR Smith 2004 Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer Urology 63 4 742 745 10.1016/j.urology.2003.10.063 15072892 (Pubitemid 38479421)
60. MR Smith H Lee F McGovern, et al. 2008 Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome Cancer 112 10 2188 2194 10.1002/cncr.23440 1:CAS:528:DC%2BD1cXmt1Cns7g%3D 18348297 (Pubitemid 351628628)
61. MR Smith H Lee MA Fallon DM Nathan 2008 Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer Urology 71 2 318 322 10.1016/j.urology.2007.08.035 18308111 (Pubitemid 351282338)
62. T Pischon H Boeing K Hoffmann, et al. 2008 General and abdominal adiposity and risk of death in Europe N Engl J Med 359 20 2105-20 10.1056/NEJMoa0801891 19005195
63. MR Smith H Lee DM Nathan 2006 Insulin sensitivity during combined androgen blockade for prostate cancer J Clin Endocrinol Metab 91 4 1305-8 10.1210/jc.2005-2507 16434464
64. JC Smith S Bennett LM Evans, et al. 2001 The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer J Clin Endocrinol Metab 86 9 4261 4267 10.1210/jc.86.9.4261 1:CAS:528:DC%2BD3MXmvFCkur0%3D 11549659 (Pubitemid 32848544)
65. RJ Segal RD Reid KS Courneya, et al. 2003 Resistance exercise in men receiving androgen deprivation therapy for prostate cancer J Clin Oncol 21 9 1653 1659 10.1200/JCO.2003.09.534 12721238 (Pubitemid 46638574)
66. F Dockery CJ Bulpitt S Agarwal M Donaldson C Rajkumar 2003 Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia Clin Sci (Lond) 104 2 195 201 10.1042/CS20020209 1:CAS:528:DC%2BD3sXmslGgtA%3D%3D (Pubitemid 36238052)
67. LM Eri P Urdal AG Bechensteen 1995 Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia J Urol 154 1 100 414 10.1016/S0022-5347(01)67239-2 1:STN:280:DyaK2M3psFSgsQ%3D%3D 7539852
68. S Lewington G Whitlock R Clarke, et al. 2007 Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 9602 1829 1839 10.1016/S0140-6736(07)61778-4 18061058 (Pubitemid 350180032)
69. J Stamler D Wentworth JD Neaton 1986 Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) Jama 256 20 2823 2828 10.1001/jama.256.20.2823 1:STN:280:DyaL2s%2FjslWktg%3D%3D 3773199 (Pubitemid 17178359)
70. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
71. TJ Wilt HE Bloomfield R MacDonald, et al. 2004 Effectiveness of statin therapy in adults with coronary heart disease Arch Intern Med 164 13 1427 1436 10.1001/archinte.164.13.1427 1:CAS:528:DC%2BD2cXmsVKqsb0%3D 15249352 (Pubitemid 38937854)
72. JP Despres B Lamarche P Mauriege, et al. 1996 Hyperinsulinemia as an independent risk factor for ischemic heart disease N Engl J Med 334 15 952 957 10.1056/NEJM199604113341504 1:CAS:528:DyaK28XislKmsbY%3D 8596596 (Pubitemid 26114161)
73. M Pyorala H Miettinen M Laakso K Pyorala 1998 Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study Circulation 98 5 398 404 1:STN:280:DyaK1cznslyqsw%3D%3D 9714089 (Pubitemid 28357941)
74. CS Fox MJ Pencina JB Meigs RS Vasan YS Levitzky RB D'Agostino Sr 2006 Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study Circulation 113 25 2914 2918 10.1161/CIRCULATIONAHA. 106.613828 16785337 (Pubitemid 44297232)
75. S Wild G Roglic A Green R Sicree H King 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 5 1047 1053 10.2337/diacare.27.5.1047 15111519 (Pubitemid 38579764)
76. CC Cowie KF Rust DD Byrd-Holt, et al. 2006 Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002 Diabetes Care 29 6 1263 1268 10.2337/dc06-0062 16732006 (Pubitemid 44125920)
77. Allibhai SMD-H, M. Sutradar R., Fleshner N.E., Warde P., Cheung A.M., Paszat, L. Impact of androgen deprivation therapy (ADT) on bone, cardiovascular, and endocrine outcomes: A propensity-matched analysis of 20,000 patients. J Clin Oncol 2008 (May 20 suppl; abstr 5012).
78. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(Suppl 1):S12-54.
79. CS Saigal JL Gore TL Krupski J Hanley M Schonlau MS Litwin 2007 Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 7 1493 1500 10.1002/cncr.22933 1:CAS:528:DC%2BD2sXhtFyqtrbL 17657815 (Pubitemid 47463063)
80. HK Tsai AV D'Amico N Sadetsky MH Chen PR Carroll 2007 Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 20 1516 1524 10.1093/jnci/djm168 17925537 (Pubitemid 351767235)
81. AV D'Amico JW Denham J Crook, et al. 2007 Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 17 2420 2425 10.1200/JCO.2006.09.3369 17557956 (Pubitemid 46999213)
82. M Roach 3rd 2007 Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk? J Clin Oncol 25 33 5325 5326 10.1200/JCO.2007.13.9931 18024880 author reply 6 (Pubitemid 350232268)
83. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urol. 2008.
84. M Roach 3rd K Bae J Speight, et al. 2008 Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 4 585 591 10.1200/JCO.2007.13.9881 18172188 (Pubitemid 351264352)
85. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2008.
86. WC Knowler E Barrett-Connor SE Fowler, et al. 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 6 393 403 10.1056/NEJMoa012512 1:CAS:528:DC%2BD38XhtVWqurc%3D 11832527 (Pubitemid 34437694)
87. BW Brown C Brauner MC Minnotte 1993 Noncancer deaths in white adult cancer patients J Natl Cancer Inst 85 12 979 987 10.1093/jnci/85.12.979 1:STN:280:DyaK3s3mslKktA%3D%3D 8496983
88. TA Pearson SN Blair SR Daniels, et al. 2002 AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee Circulation 106 3 388 391 10.1161/01.CIR.0000020190.45892.75 12119259 (Pubitemid 34778969)